Eric Tsao, Ph.d.

Biography

 Dr. Eric Tsao has served as the Chief Executive Officer of Synermore Biologics since the founding of the company in 2013. He has over 25 years of direct experience with more than 20 products in clinical development, four US and EU approved products on the market, and eight biotech manufacturing facilities. His areas of expertise include biological product development, process design, facility engineering, and operations. Since 2008, Dr. Tsao has worked with Morningside Venture on biotech investments. He was instrumental in enhancing portfolio companies’ CMC capabilities. He was the Vice President of Technical Operations at Aeras leading the Process Development, Manufacturing, Quality Control, and Facility Engineering functions. At MedImmune, Dr. Tsao rose to the position of Vice President of Process and Manufacturing Sciences responsible at different times for the process development as well as clinical and commercial manufacturing of monoclonal antibodies and recombinant vaccines. The development and manufacturing efforts led to the successful licensing of Synagis, FluMist, and Cervarix. He was a process development scientist at Johnson & Johnson, where he focused on the development of cell culture processes and start-up of the commercial manufacturing facility for erythropoietin. Dr. Tsao received his Ph.D. in Chemical Engineering from the University of Michigan and a B.S. in Chemical Engineering from Tunghai University in Taiwan.

Research Interest

 Molecular Biology and Molecular Genetics